1 min read
Add as a preferred source on Google

Biogen’s Diranersen Data Show Slower Alzheimer’s Decline Over Two Years

The Phase 2 open-label extension showed a 38% improvement in clinical benefit with a 60 mg regimen given twice yearly.

An amber vial and two sterile syringes rest on sculpted stone / TokenPost.ai
An amber vial and two sterile syringes rest on sculpted stone / TokenPost.ai

Biogen released two-year Phase 2 extension findings Tuesday for diranersen in early Alzheimer’s disease, describing slower clinical decline and a 38% improvement in clinical benefit with 60 mg given twice a year.

The results came from an open-label extension of a Phase 2 study.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…